文献速递主动脉疾病

EVAR后IA型内漏的处理:移植物取出与定制开窗腔内修复的比较

Management of Type IA Endoleak After EVAR by Explantation or Custom Made Fenestrated Endovascular Aortic Aneurysm Repair.
PubMed 文献 · Eur J Vasc Endovasc Surg · 2021-01-04

该单中心回顾性研究比较了EVAR后IA型内漏的两种处理策略:移植物取出(EXP)与定制开窗EVAR(F-EVAR)。

要点

  • F-EVAR与EXP治疗EVAR后IA型内漏的30天死亡率和二次干预率相当。
  • EXP仍是相关选择,因F-EVAR适用性有限且EXP结果可接受。

核心结论

  • 在高容量中心,开放取出和开窗腔内修复治疗EVAR后IA型内漏均可获得满意结果。
  • F-EVAR与早期并发症发生率降低相关。
  • 开放取出仍是相关选择,因其结果可接受且F-EVAR适用性有限。

研究设计与样本

  • 回顾性单中心分析,纳入2009年至2018年因EVAR后IA型内漏接受EXP或F-EVAR治疗的患者。
  • 手术方式选择基于形态学因素(F-EVAR适用性)、瘤囊生长速率、急诊表现和/或患者症状。

主要发现

  • 两组合并症和手术时年龄相当。
  • 初始EVAR至再次干预的中位时间为60.4个月(34-85个月),组间无差异。
  • 30天二次干预率(EXP: 11.5% vs F-EVAR: 9.1%)和死亡率(EXP: 3.8% vs F-EVAR: 3.3%)组间无差异。

关键数值与推荐

  • 30天二次干预率:EXP组11.5%,F-EVAR组9.1%。
  • 30天死亡率:EXP组3.8%,F-EVAR组3.3%。
  • 1年生存率:EXP组84.0%,F-EVAR组86.6%。

临床怎么用

  • 对于EVAR后IA型内漏,F-EVAR可作为优先考虑以降低早期主要不良事件。
  • 开放取出仍是F-EVAR不适用或形态学不合适患者的重要选择。
  • 治疗决策应基于形态学适用性、瘤囊生长速率、急诊表现和症状综合判断。

局限性

  • 治疗选择非随机,存在选择偏倚。
  • 原文未报告长期随访的详细结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Proximal type 1 endoleak after endovascular abdominal aortic aneurysmal repair (EVAR) remains challenging to solve with no existing consensus. This work aims to compare two different surgical strategies to remedy type IA endoleak: endograft explantation (EXP) and aortic reconstruction or relining by custom made fenestrated EVAR (F-EVAR). METHODS: A retrospective single centre analysis between 2009 and 2018 was conducted including patients treated for type IA endoleak after EVAR with either EXP or F-EVAR. The choice of surgical technique was based on morphological factors (F-EVAR eligibility), sac growth rate, emergency presentation and/or patient symptoms. Technical success, morbidity, secondary interventions, 30 day mortality, and long term survival according to Kaplan-Meier were determined for each group and compared. RESULTS: Fifty-nine patients (91% male, mean age 79 years) underwent either EXP (n = 26) or F-EVAR (n = 33) during the study period. The two groups were equivalent in terms of comorbidity and age at the time of procedure. The median time from initial EVAR was 60.4 months (34-85 months), with no difference between groups. The maximum aneurysm diameter was greater in the EXP group compared with the F-EVAR group, 86 mm (65-100) and 70 mm (60-80), respectively (p = .008). Thirty day secondary intervention (EXP: 11.5% vs. F-EVAR: 9.1%) and mortality (EXP: 3.8% vs. F-EVAR: 3.3%) rates did not differ between groups, while major adverse events at 30 days, defined by the current SVS guidelines, were lower in the F-EVAR group (2.4% vs. 13.6%; p = .016). One year survival rates were similar between the groups (EXP: 84.0% vs. F-EVAR: 86.6%). CONCLUSION: Open explantation and endovascular management with a fenestrated device for type IA endoleak after EVAR can be achieved in high volume centres with satisfactory results. F-EVAR is associated with decreased early morbidity. Open explantation is a relevant option because of acceptable outcomes and the limited applicability of F-EVAR.

来源:Eur J Vasc Endovasc Surg,查看原文。版权归原作者所有。

引用

  1. Doumenc B, Mesnard T, Patterson BO, et al. Management of Type IA Endoleak After EVAR by Explantation or Custom Made Fenestrated Endovascular Aortic Aneurysm Repair. Eur J Vasc Endovasc Surg. 2021. PMID: 33414067. doi:10.1016/j.ejvs.2020.10.033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。